Copy Link Print Information

Gefitinib dihydrochloride

(Synonyms: ZD 1839 dihydrochloride)
214 Cited Publications
Customer Review

Based on 214 publication(s) in Google Scholar

Gefitinib (ZD 1839) dihydrochloride is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib dihydrochloride selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib dihydrochloride also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .

For research use only. We do not sell to patients.

  • CAS No.: 184475-56-7
  • Formula: C22H26Cl3FN4O3
  • Molecular Weight:519.82
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Gefitinib dihydrochloride Chemical Structure
    Gefitinib dihydrochloride Chemical Structure
  • Experimental Validation Results for Gefitinib dihydrochloride
  • Experimental Validation Results for Gefitinib dihydrochloride
  • Experimental Validation Results for Gefitinib dihydrochloride
  • Experimental Validation Results for Gefitinib dihydrochloride
  • Experimental Validation Results for Gefitinib dihydrochloride
  • Experimental Validation Results for Gefitinib dihydrochloride
  • Experimental Validation Results for Gefitinib dihydrochloride
  • Experimental Validation Results for Gefitinib dihydrochloride
  • Experimental Validation Results for Gefitinib dihydrochloride
  • Experimental Validation Results for Gefitinib dihydrochloride
  • Experimental Validation Results for Gefitinib dihydrochloride
  • Experimental Validation Results for Gefitinib dihydrochloride
CAS No.: 184475-56-7
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Gefitinib dihydrochloride:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Gefitinib dihydrochloride

More
Customer Validation & Images
WBCell Proliferation/Viability AssayIF
  • Cell Proliferation/Viability Assay
  • WB
  • IF
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB

All EGFR Isoforms

More
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Gefitinib dihydrochloride Chemical Structure
    Gefitinib dihydrochloride Chemical Structure
    1/16
  • 1/16

    Gefitinib dihydrochloride purchased from MedChemExpress. Usage Cited in: Kaohsiung J Med Sci. 2023 Jul;39(7):699-709. [Abstract]

    Customer Validation
     Gefitinib (0-20 μM; 24 h) significantly inhibits the viability of A549 cells.

  • 1/16

    Gefitinib dihydrochloride purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Oct;30(10):833-853. [Abstract]

    Customer Validation
     Western blot showing EGFR phosphorylation (Y1173 and Y1068) as a biomarker of EGFR activation following treatment with erlotinib or gefitinib (0.2-1 μM) for 24 hours in sphere culture at the indicated concentrations.

  • 1/16

    Gefitinib dihydrochloride purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Oct;30(10):833-853. [Abstract]

    Customer Validation
     Immunofluorescence showing phospho-EGFR (Y1173) expression in GSCs in 3D tetracultures following treatment with 1μM of erlotinib or gefitinib for 24 hours. Scale bar, 25μm.

  • 1/16

    Gefitinib dihydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2018 Jun 11;33(6):1061-1077.e6. [Abstract]

    Customer Validation
     WT mice are either treated with vehicle or Gefitinib (100 mg/kg/day) starting one day prior to DEN injection (100 mg/kg). Livers are collected at 3 and 48 hr after DEN injection and subjected to IB analyses with the indicated antibodies.

  • 1/16

    Gefitinib dihydrochloride purchased from MedChemExpress. Usage Cited in: Theranostics. 2018 Jul 30;8(15):4262-4278. [Abstract]

    Customer Validation
     BV2 cells are pretreated with 0.1% DMSO (Ctrl), JuA (25 µM) or JuA (25 µM) with the indicated antagonist of RTKs (Dovitinib at 1 µM, Gefitinib at 2.5 µM, SU 11248 at 2.5 µM and LDC1267 at 1 µM) for 30 min, followed by administration of Aβ42 (5 μM) for 12 h.

  • 1/16

    Gefitinib dihydrochloride purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Feb 15;9(3):269. [Abstract]

    Customer Validation
     WB is used to detect the effect of EGF treatment for 4 h on the expression of YAP with the inhibitors of EGFR or its downsream members, including Gefitinib, LY294002, Wortmannin, GSK2334470, BX-795, MK-2206, GSK1120212, and U0126 in the Si RhoA transfected HepG2 and SMMC7721 cells for 48 h in HepG2 and SMMC7721 cells.

  • 1/16

    Gefitinib dihydrochloride purchased from MedChemExpress. Usage Cited in: Oncogene. 2018 Aug;37(31):4300-4312. [Abstract]

    Customer Validation
     Western blot analysis of E-cadherin and vimentin in HCC827 xenograft tumors treated with Gefitinib daily for 6-8 weeks until tumors regrown (resistant) or saline for 1 week (sensitive) (left panel).

  • 1/16

    Gefitinib dihydrochloride purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Oct;40(4):2242-2250. [Abstract]

    Customer Validation
     Effects of Gefitinib(G) and SC 58635 (Cel) on ABCB1 (MDR1), FOXM1 and Bcl 2 protein levels in PC3/DR and DU145/DR cell lines. The effects of Gefitinib, SC 58635 and their combination on ABCB1 (MDR1), FOXM1 and Bcl 2 expression in the PC3/DR and DU145/DR cell lines are determined by a western blot assay.

  • 1/16

    Gefitinib dihydrochloride purchased from MedChemExpress. Usage Cited in: Breast Cancer Res. 2017 Aug 4;19(1):90. [Abstract]

    Customer Validation
     The effect of Gefitinib-FTY720 treatment on CD44 expression in TNBC cell lines. HCC1806, Hs578T, and MDA-MB-468 TNBC cell lines at ~40% confluence in 12-well plates are exposed for 24 h to Gefitinib (Gef: 0.1 to 10 μM), with or without the addition of 1.5 μM FTY720.

  • 1/16

    Gefitinib dihydrochloride purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2017 Sep;16(3):3475-3481. [Abstract]

    Customer Validation
     Cyclin B1 and Cdk1 protein expression levels are significantly downregulated in NCI-H1975 cells treated with the combination of DHA (5 µM) and Gefitinib (10 µM).

  • 1/16

    Gefitinib dihydrochloride purchased from MedChemExpress. Usage Cited in: Exp Cell Res. 2017 Dec 15;361(2):246-256. [Abstract]

    Customer Validation
     Western blot analysis for p21, p-p21, Cyclin D1. Bcl-2, Caspase 3, Cleaved Caspase 3, Caspase 9, Cleaved Caspase 9 and Bax in HCC827-GR and PC-9-GR cells treated with control, Efatutazone alone, Gefitinib alone, or Efatutazone combined with gefitinib for 48 h.

  • 1/16

    Gefitinib dihydrochloride purchased from MedChemExpress. Usage Cited in: Chem Pharm Bull (Tokyo). 2017 Aug 1;65(8):768-775. [Abstract]

    Customer Validation
     Changes in Bcl-2 protein expression in MCF-7 cells after treatment with 2CdA, BMS-354825 or Gefitinib alone or in combination for 12 h. Expression of Bcl-2 protein is analyzed by western blotting analysis.

  • Gefitinib dihydrochloride